News - Organon
WEBAug 6, 2024 · Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%. September 17, 2024. Organon Issues 2023 ESG Report, Highlighting Strides in Women’s Health Equity and Environmental Stewardship. September 12, 2024.
Organon to Acquire Dermavant including its Innovative …
WEB5 days ago · VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon’s international dermatology capabilities to the U.S. JERSEY CITY, N.J., September 18, 2024 – Organon (NYSE: OGN), a global healthcare company with a mission to improve ...
Organon & Co. (OGN) Latest Stock News & Headlines - Yahoo …
WEBGet the latest Organon & Co. (OGN) stock news and headlines to help you in your trading and investing decisions.
Organon to Acquire Dermavant including its Innovative …
WEB5 days ago · BASEL, Switzerland and LONDON and NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives ...
Organon makes $1.2bn play for Roivant’s immuno-dermatology …
WEB4 days ago · In this article: Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the ...
Organon Reports Results for the Fourth Quarter and Full Year …
WEBDec 31, 2023 · Total revenue was $6.3 billion for full year 2023, an increase of 1% as-reported and an increase of 3% ex-FX, compared with the full year 2022. Women’s Health revenue increased 2% as-reported and 3% ex-FX for full year 2023 compared with 2022.
Assessing Organon’s Strategic Acquisition of ... - Markets Insider
WEB4 days ago · Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women’s health, biosimilars, and ...
Organon: A Surprising Deal (NYSE:OGN) | Seeking Alpha
WEB1 day ago · The business finally stabilized in 2023, with sales reported up 1% to $6.26 billion, aided by a strong fourth quarter during which Organon benefited from supply chain re-stocking and temporary ...
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been …
WEBFeb 20, 2024 · JERSEY CITY, N.J.-- (BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.
Merck Announces Completion of Organon & Co. Spinoff
WEBJun 3, 2021 · “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable growth and value,” said Rob Davis, president, Merck.